Polycystic Ovarian Syndrome Treatment Market Size & Share 2024 - 2032

Polycystic Ovarian Syndrome Treatment Market Size

Polycystic Ovarian Syndrome Treatment Market was valued at USD 5.6 billion in 2023 and is anticipated to witness growth at a CAGR of 5.8% over the analysis period. The increasing prevalence of PCOS, attributed to lifestyle changes and rising obesity rates, has led to a greater demand for treatments.

For instance, as per the National Institute of Health (NIH), the estimated global prevalence of PCOS among women of reproductive age (15–49 years) is between 5% and 15%. Increasing number of women being diagnosed with PCOS, increases the demand for effective medications, thereby boosting the market growth. Additionally, enhanced awareness and diagnosis of the condition have further expanded the patient pool seeking medical intervention. Furthermore, the growing emphasis on women's health and fertility, alongside the expansion of healthcare infrastructure in emerging markets, also significantly contributes to the market's expansion.
 

Polycystic ovarian syndrome (PCOS) treatment refers to the medical management and therapeutic strategies used to alleviate symptoms and address the underlying hormonal imbalance in individuals with PCOS. PCOS is a common endocrine disorder characterized by irregular menstrual cycles, hyperandrogenism (excess levels of male hormones), and polycystic ovaries. The treatment for PCOS is typically tailored to the patient's symptoms, reproductive goals, and overall health.

Polycystic Ovarian Syndrome Treatment Market Trends

• The rising incidence of polycystic ovarian syndrome (PCOS) among women of reproductive age is significantly driving the market.
   
• This condition, characterized by hormonal imbalances, irregular menstrual cycles, and ovarian cysts, is increasingly being diagnosed due to heightened awareness and improved diagnostic techniques.
   
• For instance, the World Health Organization (WHO) data suggests that approximately 116 million women (3.4%) are affected by PCOS globally. Further, up to 70% of affected women remain undiagnosed worldwide.
   
• As more women experience the symptoms and complications associated with PCOS, the demand for effective treatment options, including medication, lifestyle interventions, and assisted reproductive technologies, has surged.
   
• This growing patient population necessitates advancements in therapeutic solutions, fostering innovation and expansion within the market.
   
• Additionally, the increasing focus on women's health and the socio-economic impacts of untreated PCOS further amplify the need for comprehensive treatment strategies, thereby propelling market growth.
   

Polycystic Ovarian Syndrome Treatment Market Analysis

Based on treatment type, the market is segmented into medications and surgery. The medications segment is further classified into the following drug classes: oral contraceptives, antiandrogen, insulin-sensitizing agents, antidepressants, anti-obesity, Selective Estrogen Receptor Modulators (SERMs), and other drug classes. The drugs market is segmented based on distribution channel into hospital pharmacies, retail pharmacies, and online pharmacies. Amongst the various medications used, the insulin-sensitizing agents segment dominated the market in 2023 and accounted for USD 1.3 billion.
 

• The insulin-sensitizing agents segment holds a high market share in the polycystic ovarian syndrome (PCOS) treatment market, driven by the widespread recognition of insulin resistance as a key underlying factor in PCOS pathophysiology.
   
• These agents, particularly metformin, are extensively prescribed to improve insulin sensitivity, thereby addressing a significant aspect of the disorder that contributes to hyperandrogenism and ovulatory dysfunction.
   
• The growing prevalence of PCOS, coupled with increasing awareness among healthcare providers and patients about the metabolic implications of the condition, further propels the demand for insulin-sensitizing agents.
   

Learn more about the key segments shaping this market

Download Free PDF

North America polycystic ovarian syndrome treatment market was valued at USD 2.2 billion in 2023 and is anticipated to reach USD 3.5 billion by 2032.
 

• The region boasts a high prevalence of PCOS, leading to increased demand for effective treatments and management options. For instance, based on the National Institutes of Health (NIH) diagnostic criteria, the prevalence of PCOS in North America is reported to be between 6% and 9%.
   
• Additionally, the robust healthcare infrastructure and widespread access to advanced medical technologies in North America facilitate early diagnosis and comprehensive care for PCOS patients.
   
• Furthermore, the presence of leading pharmaceutical companies and ongoing research initiatives aimed at developing novel therapeutics contribute to market growth.
   

The U.S. market is anticipated to grow at a CAGR of 5.2% between 2024 - 2032.
 

• The prevalence of PCOS among women of reproductive age in the U.S. is significant, driving the demand for effective treatments.
   
• Additionally, the U.S. healthcare system's advanced infrastructure and the availability of a wide range of treatment options, including pharmaceuticals and lifestyle management programs, contribute to the market's growth.
   
• Moreover, increasing awareness about PCOS and the importance of early diagnosis and treatment among the population supports the market's expansion.
   

UK is anticipated to witness robust growth in the global polycystic ovarian syndrome treatment market.
 

• Increasing awareness of PCOS among women and healthcare professionals has led to earlier diagnosis and a higher demand for effective treatments in the country.
   
• Additionally, government initiatives and funding to improve women's health services, coupled with a robust healthcare infrastructure, further support the market expansion.
   
• Moreover, the rising prevalence of obesity and sedentary lifestyles, which are risk factors for PCOS, contribute to the growing patient pool requiring treatment. This combination of factors positions the UK as a burgeoning market for PCOS treatment, attracting both domestic and international pharmaceutical companies to invest and innovate in this sector.
   

India polycystic ovarian syndrome treatment industry is anticipated to witness lucrative growth between 2024 – 2032.
 

• Increasing awareness about PCOS among women, coupled with the rising prevalence of the syndrome, has led to a growing demand for effective treatments.
•  
• For instance, as per a study report, the prevalence of PCOS in India ranges from 3.7 to 22.5% depending on the population studied and the criteria used for diagnosis.
   
• Additionally, advancements in healthcare infrastructure and the availability of a wide range of treatment options have contributed to the market's growth.
   
• Furthermore, government initiatives to improve women's health and the presence of key market players focusing on research and development of novel treatments have also fueled the expansion of the PCOS treatment market in India.
   

Polycystic Ovarian Syndrome Treatment Market Share

The competitive landscape of the polycystic ovarian syndrome (PCOS) treatment market is characterized by a mix of pharmaceutical companies, biotech firms, and healthcare providers offering a range of treatment options. Major players in the market include pharmaceutical giants like Bayer AG, Merck & Co., Inc., and Pfizer Inc., which offer medications such as oral contraceptives, anti-androgens, and insulin-sensitizing agents. Overall, the PCOS treatment market is highly competitive, with companies constantly innovating to meet the growing demand for effective and safe treatment options.
 

Polycystic Ovarian Syndrome Treatment Market Companies

Prominent players operating in the industry include:

• Abbott Laboratories
• AbbVie Plc
• Addex Therapeutics Ltd.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myer Squibb Company
• Ferring BV
• Johnson and Johnson
• Merck KGaA
• Mylan N.V
• Novartis AG
• Pfizer Inc.
• Sanofi SA
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Limited
   

Polycystic Ovarian Syndrome Treatment Industry News:

• In December 2021, Organon, a global women's healthcare company, acquired Forendo Pharma, a clinical-stage drug development company focused on novel treatments in women's health. Forendo's pipeline includes a preclinical program targeting polycystic ovarian syndrome (PCOS).
   
• In January 2020, Evotec SE and Bayer AG announced the expansion of their partnership in women’s health indications with a new five-year, multi-target collaboration to develop multiple clinical candidates for the treatment of polycystic ovary syndrome (“PCOS”). The alliance aimed to translate first-in-class science and drug discovery into new drugs for PCOS, addressing the high unmet medical need for women suffering from this condition.
   

The polycystic ovarian syndrome treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 - 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• Medications
  • By Drug Class
    • Oral contraceptives
    • Antiandrogen
    • Insulin-sensitizing agents
    • Antidepressants
    • Anti-obesity
    • Selective Estrogen Receptor Modulators (SERMs)
    • Other drug classes
  • By Distribution Channel
    • Hospital pharmacies
    • Retail pharmacies
    • Online pharmacies
• Surgery
  • Ovarian wedge resection
  • Laparoscopic ovarian drilling
  • Other surgeries

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa